EMA Authorised: Dawnzera (donidalorsen) — Otsuka Pharmaceutical Netherlands B.V.

View source ↗

Summary

EMA authorised Dawnzera (donidalorsen) for hereditary angioedema. The product is developed by Otsuka Pharmaceutical Netherlands B.V.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• DAWNZERA (DONIDALORSEN)

Snippet

Status: Authorised. Therapeutic area: Angioedemas, Hereditary. MAH: Otsuka Pharmaceutical Netherlands B.V.. Decision date: 19/01/2026